By Mariam Sunny and Michael Erman Feb 26 (Reuters) - Novavax raised its adjusted revenue forecast for 2026 on Thursday, ...
The Food and Drug Administration authorized Novavax's single-strain vaccine, which targets omicron subvariant XBB.1.5, for emergency use in people ages 12 and up. The Centers for Disease Control and ...
Novavax Inc. NVAX shares are up on Thursday following the company’s announcement of its fourth-quarter and full-year 2025 financial results. Earnings Novavax reported fourth-quarter earnings of 11 ...
GAITHERSBURG, Md., May 12, 2023 /PRNewswire/ -- Novavax, Inc. (NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that the Singapore Health ...
The Biden administration announced Monday that it would purchase 3.2 million doses of the Novavax COVID-19 vaccine. It will be offered at no cost to states and federal partners. “We remain committed ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min It’s the second time the firm ...
Jan 20 (Reuters) - Novavax said on Tuesday it signed a licensing agreement allowing Pfizer access to its technology that boosts immune responses to vaccines for use in up to two infectious diseases, ...
Novavax could pay up to $475 million to the organization, but the total amount may be less if Gavi decides to order more shots from the cash-strapped company over the next five years. Still, the ...
Feb 26 (Reuters) - Novavax raised its adjusted revenue forecast for 2026 on Thursday, banking on milestone payments from licensing and supply deals for its shots, although it noted that the current ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results